VYNE Therapeutics Inc. Sustainability Profile
VYNE Therapeutics Inc., a biopharmaceutical company headquartered in the United States, is dedicated to developing innovative therapies for patients with unmet medical needs. Founded in 2017, VYNE focuses on dermatology and immunology, leveraging its proprietary drug delivery technologies to create unique formulations that enhance treatment efficacy. The company’s flagship product, Amzeeq, is a topical minocycline formulation that addresses acne vulgaris, showcasing VYNE's commitment to advancing patient care through novel solutions. With a strong market position, VYNE Therapeutics has achieved significant milestones, including successful product launches and strategic partnerships, solidifying its reputation as a leader in the biopharmaceutical industry.
DitchCarbon Score
How does VYNE Therapeutics Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
VYNE Therapeutics Inc.'s score of 23 is lower than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
VYNE Therapeutics Inc.'s reported carbon emissions
VYNE Therapeutics Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that VYNE may not have established formal commitments to reduce its carbon footprint or engage in climate initiatives at this time. As the industry increasingly prioritises sustainability, VYNE's future climate commitments will be crucial for aligning with broader environmental goals.
How Carbon Intensive is VYNE Therapeutics Inc.'s Industry?
How Carbon Intensive is VYNE Therapeutics Inc.'s Location?
VYNE Therapeutics Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
VYNE Therapeutics Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
